# Organon account plan

> Organon is a global healthcare company in women's health and general medicines with FY2025 revenues of $6,216 million, being acquired by Sun Pharma.

## At a glance

Organon & Co., spun off from Merck in 2021 and headquartered in Jersey City, New Jersey, sells a portfolio of over 70 products across women's health and general medicines (biosimilars and established brands) in over 140 countries and territories. FY2025 revenues were $6,216 million, down 3%, with approximately 74% generated outside the United States; net income was $187 million and adjusted EBITDA $1.9 billion. It had over 10,000 employees at year-end 2025 and six owned plants in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the UK. On April 26, 2026 it agreed to be acquired by Sun Pharma for $14.00 per share in cash, with closing expected by early 2027.

## Business units

- **Established Brands** (approximately 59% of FY2025 revenues ($3,691 million)): Mature brands in cardiovascular, respiratory, dermatology, bone health and non-opioid pain, approximately 91% sold outside the United States, such as Zetia, Atozet, Singulair, Nasonex and Arcoxia. Vtama (psoriasis and atopic dermatitis) and Emgality (migraine) are growing, while Atozet and Singulair decline on loss of exclusivity and price cuts.
- **Women's Health** (approximately 28% of FY2025 revenues ($1,752 million)): Contraception (Nexplanon, NuvaRing, Marvelon) and fertility (Follistim AQ) products, sold in over 90 markets. Nexplanon, the largest brand, fell 10% to $200 million in Q3 2026 as US reinsertions were delayed after the five-year label; the Jada device was sold to Laborie in January 2026.
- **Biosimilars** (approximately 11% of FY2025 revenues ($691 million)): Immunology and oncology biosimilars developed with Samsung Bioepis, Henlius and Bio-Thera, including Hadlima, Renflexis and the denosumab biosimilars Bildyos and Bilprevda. Hadlima grew 35% to $86 million in Q3 2026; a pertuzumab biosimilar is planned for US launch in 2028.

## Strategic priorities

- **Deleveraging**: Reduce net leverage from approximately 4.3x at end-2025 to below 4 times by the end of 2026, with the dividend cut to $0.02 per quarter, the Jada divestiture and debt repurchases.
- **Cost savings**: Over $200 million in cost savings in 2025, and another round of opex savings built into 2026 guidance.
- **Revenue growth from newer products**: Volume growth of about $150 million in 2026 from Vtama (expected to grow 20-25%), Emgality, biosimilars and Nexplanon outside the US.
- **Late-stage business development**: Favour later-stage or marketed women's health assets, such as the Miudella hormone-free copper IUD licensed from Sebela, over early-stage R&D.
- **Manufacturing separation from Merck**: Exit supply agreements with Merck through 2031, which should support gross margin expansion from 2027.
- **Close the Sun Pharma acquisition**: Stockholders approved the $14.00 per share cash deal on July 23, 2026; regulatory approvals are pending, with closing expected by early 2027.

## Latest results

In Q3 2026 (quarter ended September 30) sales were $1,574 million, down 2% (down 3% ex-FX), with US sales $411 million (+1%) and International $1,163 million (-3%). Net income was $164 million against $160 million a year earlier, and interest expense fell 17% to $106 million. Nexplanon fell 10% while Hadlima, Vtama and Emgality grew; supply constraints cut revenue by less than 2%. Nine-month sales were $4,592 million (down 2%), and cash rose to $1.46 billion. FY2026 guidance given in February 2026 was about $6.2 billion of revenue and about $1.9 billion of adjusted EBITDA.

## Investments and deals

- **Jada divestiture**: Sold to Laborie in January 2026 for up to $465 million ($440 million plus up to $25 million earnout), with net proceeds of approximately $390 million used to reduce debt.
- **Miudella licence**: February 19, 2026 exclusive global licence from Sebela for a hormone-free copper IUD; $27.5 million paid in June 2026, with sales milestones up to $505 million and US launch estimated in late 2026.
- **Biosimilar portfolio changes**: Tofidence US rights acquired from Biogen in March 2025, and Samsung Bioepis amendments adding Pyzchiva in Canada and Epyztek in Australia while returning Ontruzant and Aybintio rights in some markets.
- **Oss Biotech site**: Fertility drug substance plant purchased from Merck in July 2025 ($25 million plus $71 million of inventory).

## Challenges and risks

- **High debt**: Debt obligations of $8.7 billion through 2034, with approximately $3.6 billion of notes maturing in 2028, and interest expense of $504 million in 2025.
- **Nexplanon pressure**: US policy restrictions at Planned Parenthood and federally qualified health centres, fewer reinsertions with the five-year label, and US rod patents expiring in 2027.
- **Loss of exclusivity and price erosion**: LOE reduced 2025 sales by approximately $197 million, China volume-based procurement weighs on general medicines, and US drug-pricing reform adds pressure.
- **Governance and controls**: An Audit Committee investigation found Nexplanon sales pushed to two US wholesalers, leading to material weaknesses, an Interim CEO and a $301 million goodwill impairment on the US unit in 2025.
- **Supply constraints**: Disruptions at a key contract manufacturer, a third-party logistics provider and geopolitical events constrained Established Brands revenue in 2026; several materials are sole-sourced.

## What leadership says

> "In 2025, Organon delivered $6.2 billion in revenue and $1.9 billion of adjusted EBITDA." — Joseph Morrissey, Interim CEO, Q4 and full-year 2025 earnings call, February 12, 2026

> "deleveraging the business, driving cost savings and achieving revenue growth." — Joseph Morrissey, Interim CEO, On his priorities, Q3 2025 earnings call, November 10, 2025

> "we don't see any strategic changes." — Carrie Cox, Executive Chair, Q3 2025 earnings call, November 10, 2025

> "net leverage below 4 times by the end of the year" — Matthew Walsh, CFO, Q4 and full-year 2025 earnings call, February 12, 2026


## Where a supplier can help

- **Supply chain resilience**: Tied to the supply constraints challenge and the Merck manufacturing separation: contract manufacturing, logistics and supplier diversification services.
- **Cost reduction and integration**: Tied to the cost savings priority and the pending Sun Pharma acquisition: operating efficiency and integration support ahead of closing.
- **Compliance and commercial controls**: Tied to the governance challenge: sales controls, training and disclosure tooling that support remediation of the material weaknesses.
- **Omnichannel commercial support for launches**: Tied to the revenue growth priority: digital and field engagement tools for Vtama international launches, Miudella and biosimilars, run by about 4,000 commercialization staff.

_Tamtam's reading of the priorities and challenges above, not the company's own words._

## Key documents

### [Form 10-K for fiscal year 2025](https://www.sec.gov/Archives/edgar/data/1821825/000162828026011125/ogn-20251231.htm)

Annual report · 2026-02-24

- Organon & Co. is a global healthcare company spun off from Merck in 2021, with a portfolio of over 70 products across women's health and general medicines (biosimilars and established brands), sold in over 140 countries and territories; HQ Jersey City, New Jersey.
- FY2025 revenues were $6.2 billion ($6,216 million), down 3% from $6,403 million in 2024; approximately 74% of revenues ($4.6 billion) were generated outside the United States. Net income fell to $187 million from $864 million.
- Mix: Established Brands $3,691 million (approximately 59% of revenues), Women's Health $1,752 million (approximately 28%), Biosimilars $691 million (approximately 11%).
- Largest brand is Nexplanon ($921 million, down 4%); the FDA approved a five-year duration of use in January 2026, but the US rod patents expire in 2027 and applicator patents in 2030.
- Growth came from Vtama ($128 million), Hadlima (+60% to $228 million) and Emgality (+63% to $174 million); declines from Atozet (-31%, loss of exclusivity), Singulair (-30%) and Dulera (-25%). LOE cut sales by approximately $197 million.
- Results hit by a $301 million goodwill impairment on the U.S. reporting unit, $95 million of restructuring costs and gross profit down 11%; R&D expenses fell 22% to $366 million as early programs (OG-6219, OG-7191) were discontinued.
- Strategy centres on deleveraging: debt obligations of $8.7 billion (approximately $3.6 billion maturing in 2028), dividend cut to $0.02 per quarter, Jada divested to Laborie in January 2026 for up to $465 million, $419 million of 2031 Notes repurchased.
- An Audit Committee investigation found the company asked two U.S. wholesalers to buy more Nexplanon than demand; material weaknesses (tone at the top) were reported, Joseph Morrissey became Interim CEO and Carrie S. Cox Executive Chair.
- Over 10,000 employees at year-end 2025 (approximately 1,500 in the U.S.), approximately 4,000 in commercialization; six owned plants in Belgium, Brazil, Indonesia, Mexico, the Netherlands and the UK.

### [Form 10-Q for the quarter ended September 30, 2026](https://www.sec.gov/Archives/edgar/data/1821825/000182182526000004/ogn-20260930.htm)

Interim report · 2026-10-30

- Form 10-Q for Q3 2026 (quarter ended September 30, 2026), filed October 30, 2026; Organon is being acquired by Sun Pharma for $14.00 per share in cash, approved by stockholders on July 23, 2026, closing expected by early 2027.
- Q3 2026 sales $1,574 million, down 2% (down 3% ex-FX); nine-month sales $4,592 million, down 2%. United States $411 million (+1%), International $1,163 million (-3%).
- Q3 net income $164 million (Q3 2025: $160 million); nine-month net income $418 million (2025: $392 million).
- Nexplanon fell 10% to $200 million in Q3 as reinsertions were delayed after the five-year US label and federal funding was uncertain; the UK approved the five-year duration in April 2026.
- Growth drivers: Hadlima +35% to $86 million, Bildyos/Bilprevda $24 million, Emgality +16% to $59 million, Vtama +21% to $42 million; Ontruzant fell 77% on lower Brazil tenders.
- Supply Constraints (a key contract manufacturer, logistics labour disruption, geopolitics) cut revenue by an estimated less than 2% in Q3 and nine months, mainly Established Brands.
- Business development: Sebela licence for Miudella (hormone-free copper IUD, $27.5 million paid, up to $505 million in milestones), Samsung Bioepis amendments adding Pyzchiva (Canada) and Epyztek (Australia), returning Ontruzant/Aybintio rights in Europe, Canada and Brazil.
- Cash rose to $1.46 billion; interest expense fell 17% in Q3; disclosure controls were concluded effective as of September 30, 2026.

### [Q4 and full-year 2025 earnings call (corrected transcript)](https://s27.q4cdn.com/703211477/files/doc_financials/2025/q4/CORRECTED-TRANSCRIPT_-Organon-Co-OGN-US-Q4-2025-Earnings-Call-12-February-2026-8_30-AM-ET.pdf)

Executive talk · Joseph Morrissey, Interim Chief Executive Officer · 2026-02-12

- Q4 and full-year 2025 earnings call (February 12, 2026), Interim CEO Joseph Morrissey, CFO Matthew Walsh, Executive Chair Carrie Cox and R&D head Juan Camilo Arjona Ferreira.
- 2025: $6.2 billion revenue and $1.9 billion adjusted EBITDA; revenue down 3%; adjusted EBITDA margin 30.7%, flat despite 150 basis points of gross-margin degradation; over $200 million in cost savings.
- 2026 guidance: about $6.2 billion revenue and about $1.9 billion adjusted EBITDA; gross margin 75-100 basis points lower; LOE about $40 million, VBP about $30 million, price about $75 million, volume growth about $150 million.
- Nexplanon: FDA approved five-year duration; 2026 expected roughly flat, with US headwinds from Planned Parenthood/FQHC access restrictions, clinics shifting to specialty pharmacy, and fewer reinsertions (about 13% of insertions), offset by Latin America.
- Biosimilars: Hadlima grew 61% ex-FX in 2025; 2026 flat to modest growth; denosumab biosimilars peak around $100 million; pertuzumab biosimilar US launch 2028.
- Established Brands: down 5% ex-FX in 2025 (Atozet LOE about 400 basis points); expected flat in 2026; Vtama to grow 20-25%; Nilemdo added in the EU.
- Balance sheet: net leverage about 4.3x; about $530 million of debt retired in 2025; Jada net proceeds about $390 million; target below 4x by end-2026.
- Cox declined questions about a new matter brought to the Audit Committee; no update on the permanent CEO search.

### [Q3 2025 earnings call (transcript)](https://s27.q4cdn.com/703211477/files/doc_financials/2025/q3/Organon-Co-OGN-US-Q3-2025-Earnings-Call-10-November-2025-8_30-AM-ET.pdf)

Executive talk · Carrie Cox, Executive Chair · 2025-11-10

- Q3 2025 earnings call (November 10, 2025), the first after the Board installed Carrie Cox as Executive Chair and Joseph Morrissey as Interim CEO following the Nexplanon wholesaler investigation.
- Cox: investigation complete, practices ceased, remediation underway (controls, personnel actions, training); search committee formed for a permanent CEO; "we don't see any strategic changes".
- Morrissey: priorities unchanged — deleveraging the business, driving cost savings and achieving revenue growth.
- CFO Walsh: "limited revenue impact and no financial restatement"; $17 million Q3 2025 pull-forward rolls off in Q4.
- Q3 revenue $1.6 billion, adjusted EBITDA $518 million (32.3% margin); 2025 revenue guidance cut to $6.2-6.25 billion and adjusted EBITDA margin to approximately 31%.
- Nexplanon $223 million in Q3, down 9% ex-FX (US -15%, international +7%) on US policy affecting Planned Parenthood and FQHCs.
- Jada divestiture for $440 million plus $25 million contingent, to speed deleveraging; net leverage approximately 4.2x.
- Vtama $34 million in Q3; 2025 now $120-130 million vs a $150 million target; peak still close to $0.5 billion. Respiratory erosion to persist into 2026.

## Questions about Organon

### What does Organon do?

Organon is a global healthcare company with over 70 products in women's health (contraception, fertility), biosimilars and established brands, sold in over 140 countries and territories.

### What is Organon's revenue?

FY2025 revenues were $6,216 million, down 3%, with about $1.9 billion of adjusted EBITDA. Q3 2026 sales were $1,574 million.

### How many employees does Organon have?

Organon had over 10,000 employees at year-end 2025, approximately 1,500 of them in the United States.

### Who leads Organon?

Joseph Morrissey has been Interim CEO since October 27, 2025, with Carrie S. Cox as Executive Chair and Matthew Walsh as CFO.

### Is Organon being acquired?

Yes. Sun Pharma agreed on April 26, 2026 to acquire Organon for $14.00 per share in cash; stockholders approved it on July 23, 2026, and closing is expected by early 2027.

_Written by Tamtam from the company's own published documents listed above, read in full. Figures are as those documents state them, for the periods they name. (2026-11-17)_
